Want to see SE:EKTA.B full AI Analyst Report?
Top Page
Elekta AB
(EKTA.B)
Select Model
Select Model
Rating:57Neutral
Price Target:
kr62.00
▲(10.62% Upside)
Action:Reiterated
Date:08/28/26
The score is driven primarily by weakened financial performance (sharp revenue decline, recent losses, and higher leverage), partially offset by strong recent free cash flow generation. Technical indicators add moderate support due to positive momentum, while valuation is balanced between a negative P/E from losses and a relatively high dividend yield.
Positive Factors
Recurring service and software model
Elekta combines capital equipment with software and recurring service revenue supported by a long-lived installed base. This mix can create continuing customer relationships and upgrade demand, reducing reliance on one-time system sales over the next several quarters.
Negative Factors
Sharp revenue decline and losses
The steep TTM revenue decline and return to net losses represent a material deterioration from profitability in 2022–2024. If this persists, weaker scale and reduced earnings capacity could constrain investment, weaken resilience, and make future growth more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring service and software model
Elekta combines capital equipment with software and recurring service revenue supported by a long-lived installed base. This mix can create continuing customer relationships and upgrade demand, reducing reliance on one-time system sales over the next several quarters.
Read all positive factors
Elekta AB (EKTA.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr22.81B
Dividend Yield3.75%
Average Volume (3M)1.19M
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth-6.90%
EPS Growth-232.45%
CountrySE
Employees3,996
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.94
Shares Outstanding368,587,650
10 Day Avg. Volume1,284,145
30 Day Avg. Volume1,194,903
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.88
Price to Sales (P/S)1.22
P/FCF Ratio8.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr45.85Price Target Upside-18.20% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)4.03
Revenue Forecast (FY)kr17.26B
Elekta AB Business Overview & Revenue Model
Company Description
Elekta AB (publ) operates as a global medical technology company, delivering advanced clinical solutions for managing cancer and various brain disorders. Its extensive oncology offerings include sophisticated radiation therapy systems such as Vers...
How the Company Makes Money
Elekta makes money primarily by selling and supporting clinical systems used in cancer care, with revenue generally coming from a mix of (1) capital equipment sales, (2) software, and (3) recurring service and support.
1) Capital equipment (hard...
Elekta AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
48
Neutral
Cash Flow
72
Positive
| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.61B | 16.72B | 18.02B | 18.12B | 16.87B | 14.55B |
| Gross Profit | 6.41B | 6.25B | 6.75B | 6.80B | 6.35B | 5.44B |
| EBITDA | 1.76B | 1.68B | 2.19B | 3.29B | 2.57B | 2.69B |
| Net Income | -362.00M | -520.00M | 237.00M | 1.30B | 943.00M | 1.15B |
Balance Sheet | ||||||
| Total Assets | 26.68B | 26.95B | 28.98B | 31.41B | 29.61B | 26.30B |
| Cash, Cash Equivalents and Short-Term Investments | 2.31B | 3.19B | 2.96B | 2.78B | 3.27B | 3.07B |
| Total Debt | 6.83B | 7.33B | 7.57B | 7.25B | 6.67B | 5.70B |
| Total Liabilities | 19.08B | 19.81B | 20.13B | 20.63B | 19.88B | 17.39B |
| Stockholders Equity | 7.56B | 7.10B | 8.80B | 10.78B | 9.73B | 8.91B |
Cash Flow | ||||||
| Free Cash Flow | 2.44B | 2.34B | 1.06B | 817.00M | 400.00M | 450.00M |
| Operating Cash Flow | 2.55B | 2.46B | 2.63B | 2.46B | 1.96B | 1.86B |
| Investing Cash Flow | -1.14B | -1.07B | -1.67B | -1.92B | -1.61B | -1.65B |
| Financing Cash Flow | -1.88B | -1.17B | -607.00M | -1.10B | -129.00M | -1.73B |
Elekta AB Technical Analysis
Positive
56.05
Price Trends
53.51
Positive
51.25
Positive
53.05
Positive
Market Momentum
1.70
Negative
68.89
Neutral
91.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EKTA.B, the sentiment is Positive. The current price of 56.05 is above the 20-day moving average (MA) of 56.03, above the 50-day MA of 53.51, and above the 200-day MA of 53.05, indicating a bullish trend. The MACD of 1.70 indicates Negative momentum. The RSI at 68.89 is Neutral, neither overbought nor oversold. The STOCH value of 91.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:EKTA.B.
Elekta AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | kr2.23B | 23.18 | ― | 1.62% | 28.75% | 138.25% | |
73 Outperform | kr3.00B | 32.16 | ― | ― | 8.40% | 0.74% | |
57 Neutral | kr22.81B | -63.25 | -4.66% | 3.75% | -6.90% | -232.45% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | kr371.09M | -28.83 | ― | ― | 54.37% | 52.22% | |
42 Neutral | kr373.36M | -7.46 | ― | ― | -2.61% | -0.28% | |
41 Neutral | kr498.65M | -6.94 | ― | ― | ― | -23.57% |
* General Sector Average
SE:EKTA.B
Elekta AB
59.70
13.44
29.06%
SE:STIL
Stille AB
248.50
68.00
37.67%
SE:SUS
Surgical Science Sweden AB
58.85
-25.15
-29.94%
SE:OSSD
OssDsign AB
3.38
-9.63
-74.04%
SE:CLBIO
Corline Biomedical AB
14.20
-5.60
-28.28%
SE:FLUO
FluoGuide A/S
30.50
-10.00
-24.69%
Elekta AB Corporate Events
Elekta names investor-led Nomination Committee ahead of 2027 AGM
Oct 30, 2026
Elekta has appointed its Nomination Committee for the 2027 Annual General Meeting in line with instructions set by shareholders at the 2024 AGM, underscoring its adherence to established governance procedures. The committee comprises Chairman of t...
Elekta data support expanded use of Gamma Knife for multiple brain metastases
Sep 29, 2026
Elekta has reported new phase 2 clinical data showing favorable cognitive outcomes for patients with up to 50 brain metastases treated using its Leksell Gamma Knife radiosurgery system, combined with Sunnybrook’s Spatially Partitioned Adapti...
Elekta’s Unity Data Boost Pancreatic Cancer Outcomes as Unity Pro Rolls Out
Sep 28, 2026
Elekta is a global leader in precision radiation medicine, developing MR-guided adaptive radiotherapy systems like Elekta Unity to support personalized, high-precision cancer treatments. With a strong international presence and integrated technolo...
Elekta Broadens Adaptive Radiotherapy Portfolio Across Modalities
Sep 27, 2026
Elekta AB has expanded its adaptive radiotherapy portfolio, unveiling new capabilities across CT- and MR-guided radiotherapy, radiosurgery and brachytherapy, all enabled by its Elekta ONE software platform. The enhancements extend adaptive workflo...
Elekta AGM Approves Dividend, Board Mandates and New Incentive Plan
Sep 3, 2026
At its 2026 Annual General Meeting, Elekta’s shareholders approved the 2025/26 accounts, granted discharge from liability to the board and executives, and backed a dividend of SEK 2.40 per share to be paid in two installments, while re-elect...
Elekta Delivers Strong Margin Gains Despite Q1 Revenue Dip
Aug 27, 2026
Elekta reported a 2 percent decline in first-quarter net sales in constant currencies, as solid growth in the Americas and Europe was offset by weaker performance in China, APJ and TIMEA. Despite softer revenue, orders grew 3 percent, driven by El...
Elekta Schedules First-Quarter 2026/27 Results Presentation for August 27
Aug 13, 2026
Elekta AB has invited analysts and investors to a presentation of its first-quarter 2026/27 results, scheduled for August 27 at 10:00 a.m. CEST, with the interim report to be published earlier that morning. Chief executive Jakob Just-Bomholt and c...
Elekta Calls 2026 AGM, Expands Voting Options for Shareholders
Jul 31, 2026
Elekta AB has called its shareholders to an Annual General Meeting to be held on September 3, 2026, at the company’s Stockholm headquarters, with registration starting half an hour before proceedings. Shareholders must be registered in Euroc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.